Results 241 to 250 of about 59,754 (305)

Marburg and Sudan virus outbreaks: are we any closer to a pan-filovirus vaccine? [PDF]

Trop Dis Travel Med Vaccines
Akingbola A, Adegbesan A, Adewole O, Olalude O, Isaiah O, Bhadmus F, Chuku J.   +6 more
europepmc   +1 more source

Investigation of Some Clinicopathologic Alterations in Cats Infected With Mycoplasma haemofelis and Candidatus Mycoplasma haemominutum in Mashhad, Iran: An Observational Cross‐Sectional Study

Veterinary Medicine and Science, Volume 12, Issue 3, May 2026.
This study detected Mycoplasma haemofelis (34.78%) and Candidatus M. haemominutum (65.21%) in 23% of Iranian cats via PCR. Infection correlated with age, gender and outdoor access (*p < 0.05), causing significant hematologic/biochemical changes. No inter‐species differences in clinical presentation emerged between Mhf and CMhm. ABSTRACT Background Data
Esmaeel Shahtahmasbi, Elham Valavi, Gholam Reza Razmi, Mahdieh Zaeemi   +3 more
wiley   +1 more source

Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation. [PDF]

World J Virol
Younas S, Farooq S, Sahu S, Mwita RP, Özdemir Ö.   +4 more
europepmc   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, Volume 183, Issue 9, Page 1747-1778, May 2026.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Human immunodeficiency virus vaccines: Advances, challenges and future perspectives. [PDF]

World J Virol
Varatharajan S, Krishnasai S, Girish C.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation. [PDF]

Hum Vaccin Immunother
Yang Y, Sun Y, Kang X, Wang Y.
europepmc   +1 more source

FNDC4 and FNDC5 Attenuate SARS‐CoV‐2 S1‐Induced Inflammatory Responses in Human Adipose Tissue

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
In obesity, reduced FNDC4 and FNDC5 amplify SARS‐CoV‐2 S1–driven inflammation in visceral adipose tissue. These adipo‐myokines limit adipocyte–macrophage inflammatory signalling, suggesting a protective role against viral‐induced adipose tissue dysfunction.
Gabriela Neira, Julia Hernández‐Castañeda, Victoria Catalán, Sara Becerril, Marina Martín, Víctor Valentí, Rafael Moncada, Camilo Silva, Javier Gómez‐Ambrosi, Javier Escalada, Gema Frühbeck, Amaia Rodríguez   +11 more
wiley   +1 more source